Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Dec 15, 2023 $32.19 $32.66 $30.20 $30.78 3 066 302
Dec 14, 2023 $31.84 $33.60 $31.12 $31.86 3 191 287
Dec 13, 2023 $27.91 $30.45 $26.96 $30.39 1 947 018
Dec 12, 2023 $28.25 $28.66 $27.40 $28.15 1 043 120
Dec 11, 2023 $28.81 $28.85 $27.11 $28.35 1 503 453
Dec 08, 2023 $29.53 $30.56 $28.85 $29.02 1 232 705
Dec 07, 2023 $29.74 $29.99 $29.05 $29.78 1 183 167
Dec 06, 2023 $30.37 $30.87 $29.71 $29.86 1 519 334
Dec 05, 2023 $30.45 $30.45 $29.20 $29.90 1 090 188
Dec 04, 2023 $30.84 $31.85 $30.05 $30.89 1 279 808
Dec 01, 2023 $29.57 $30.85 $28.46 $30.84 1 538 281
Nov 30, 2023 $31.36 $31.86 $29.43 $29.63 1 444 492
Nov 29, 2023 $31.32 $32.39 $30.66 $30.93 1 236 422
Nov 28, 2023 $30.49 $31.27 $29.82 $30.75 1 106 097
Nov 27, 2023 $30.88 $31.15 $29.57 $30.65 1 107 557
Nov 24, 2023 $30.13 $31.90 $30.13 $31.03 1 218 243
Nov 22, 2023 $29.01 $30.42 $28.94 $30.26 1 418 605
Nov 21, 2023 $29.84 $29.84 $28.43 $28.46 1 129 735
Nov 20, 2023 $28.57 $31.59 $28.32 $30.28 2 818 572
Nov 17, 2023 $26.36 $28.17 $26.18 $28.12 1 894 143
Nov 16, 2023 $26.60 $27.08 $25.20 $26.02 1 135 576
Nov 15, 2023 $26.65 $27.70 $26.52 $26.58 1 678 945
Nov 14, 2023 $25.35 $26.68 $25.29 $26.45 2 285 507
Nov 13, 2023 $23.90 $24.30 $22.67 $23.81 1 446 078
Nov 10, 2023 $25.06 $25.14 $22.76 $24.13 2 298 796
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT